Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Alterity Therapeutics LimitedNASDAQ: ATHE

Research & Development · Q2 FY2026 · quarter ended Dec 2025

Research & development grows 34.6% year over year

Q2 FY2026 research & development of A$7.7M rose 34.6% year over year. Over 3 fiscal years it compounded at -0.8% a year.

Context

  • Research & development amounted to 264.8% of revenue in FY2025, down 199.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$7.7M— QoQ
Last fiscal yearJun 2025
A$14.4M-22.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.6%——
1 year-22.7%——
3-year CAGR-0.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

AUD · from the income statement

Latest · FY2025
14.4M AUD
Year-over-year change
-22.7%
4-year CAGR
+4.1%

Research & Development vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.7% is the lowest of 4, against a peer median of +36.6%.
  • Research & development amounts to 264.8% of revenue for ATHE, versus a peer median of 64.3%.
ATHE Competitors
Research & Development for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$16.74B USD+90463.6%+15.1%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$14.87M USD+36.6%+1076.5%—
ATHEAlterity Therapeutics LimitedFY2025A$14.4M AUD-22.7%-0.8%264.8%
DYAIDyadic International, Inc.LTM Mar 2026$1.91M USD-5.1%-21.8%64.3%
Peer median (excluding ATHE) —+36.6%+15.1%64.3%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.